Fentanyl (transmucosal)

Gomez-Batiste, 2002, Breakthrough cancer pain: prevalence and characteristics in Catalonia, J Pain Symptom Manage, 24, 45, 10.1016/S0885-3924(02)00421-9 Zeppetella, 2008, Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief, J Pain Symptom Manage, 35, 563, 10.1016/j.jpainsymman.2007.06.012 Darwish, 2007, Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate, J Clin Pharmacol, 47, 343, 10.1177/0091270006297749 European Medicines Agency. Assessment report for Pecfent. 2010. Procedure No. EMA/H/C/001164. European Medicines Agency. Effentora: EPAR - Scientific discussion. 2008. Vasisht, 2010, Single-dose pharmacokinetics of fentanyl buccal soluble film, Pain Med, 11, 1017, 10.1111/j.1526-4637.2010.00875.x Finn, 2012, Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study, Clin Drug Investig, 32, 63, 10.2165/11594670-000000000-00000 Lichtor, 1999, (1999) The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain, Anesth Analg, 89, 732, 10.1213/00000539-199909000-00038 Darwish, 2007, Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study, Clin Drug Investig, 27, 605, 10.2165/00044011-200727090-00002 Finn, 2011, Absorption and tolerability of fentanyl buccal soluble film (FBSF) in patients with cancer in the presence of oral mucositis, J Pain Res, 4, 245 2009, Center for drug evaluation and research, Summary review Darwish, 2006, Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics, Clinical Pharmacokinet, 45, 843, 10.2165/00003088-200645080-00006 Kaasa, 2010, Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain, Journal of Opioid Manag, 6, 17, 10.5055/jom.2010.0001 European Medicines Agency. Assessment report for Instanyl. 2009. Procedure No. EMEA/H/C/959. London. Darwish, 2006, Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microgram in healthy adult volunteers, Clin Ther, 28, 707, 10.1016/j.clinthera.2006.05.015 Vasisht, 2010, Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers, J Clin Pharmacol, 50, 785, 10.1177/0091270010361354 Darwish, 2007, Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers, J Clin Pharmacol, 47, 56, 10.1177/0091270006294129 Rauck, 2009, Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain, Curr Med Res Opin, 25, 2877, 10.1185/03007990903368310 Slatkin, 2007, Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain, J Support Oncol, 5, 327 Portenoy, 2010, A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain, Pain, 151, 617, 10.1016/j.pain.2010.07.028 Portenoy, 2010, Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients, J Opioid Manag, 6, 319, 10.5055/jom.2010.0029 Rauck, 2010, Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study, Ann Oncol, 21, 1308, 10.1093/annonc/mdp541 European Medicines Agency. Committee for medicinal products for human use (CHMP). 2008. Opinion following article 29(4) referral for Rapinyl. Dworkin, 2008, Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations, J Pain, 9, 105 Kress, 2009, Clin Ther, 31, 1177, 10.1016/j.clinthera.2009.05.022 Prostraken. Personal communication, 2010. Coluzzi, 2001, Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR), Pain, 91, 123, 10.1016/S0304-3959(00)00427-9 Zeppetella, 2010, Consistent and clinically relevant effects with fentanyl buccal tablet in the treatment of patients receiving maintenance opioid therapy and experiencing cancer-related breakthrough pain, Pain Pract, 10, 287, 10.1111/j.1533-2500.2010.00359.x Ashburn, 2011, The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain, Anesth Analg, 112, 693, 10.1213/ANE.0b013e318209d320 Fallon, 2011, Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study, J Support Oncol, 9, 224, 10.1016/j.suponc.2011.07.004 Davies, 2011, Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain, J Pain Symptom Manage, 41, 358, 10.1016/j.jpainsymman.2010.11.004 Mercadante, 2009, A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open label, randomised, crossover trial, Curr Med Res Opin, 25, 2805, 10.1185/03007990903336135 Säwe, 1983, Steady-state kinetics and analgesic effect of oral morphine in cancer patients, Eur J Clin Pharmacol, 24, 537, 10.1007/BF00609900 Freye, 2007, Effervescent morphine results in faster relief of breakthrough pain in patients compared to immediate release morphine sulfate tablet, Pain Pract, 7, 324, 10.1111/j.1533-2500.2007.00157.x England, 2011, How practical are transmuscosal fentanyl products for breakthrough cancer pain? Novel use of placebo formulations to survey user opinion, BMJ Support Palliat Care, 1, 349, 10.1136/bmjspcare-2011-000037 Gardner-Nix, 2001, Oral transmucosal fentanyl and sufentanil for incident pain, J Pain Symptom Manage, 22, 627, 10.1016/S0885-3924(01)00321-9 Zeppetella, 2001, Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study, Palliat Med, 15, 323, 10.1191/026921601678320304 Palliativedrugs.com. Hot Topics: alternatives to sublingual fentanyl. In: August 2003 Newsletter. Available from www.palliativedrugs.com. Duncan, 2002, The use of fentanyl and alfentanil sprays for episodic pain, Palliat Med, 16, 550, 10.1191/0269216302pm610xx Finn, 2010, Intranasal fentanyl for analgesia in the paediatric emergency department, Emerg Med J, 27, 300, 10.1136/emj.2008.070474 Cole, 2009, Intranasal fentanyl in 1-3-year-olds: a prospective study of the effectiveness of intranasal fentanyl as acute analgesia, Emerg Med Australas, 21, 395 Mudd, 2011, Intranasal fentanyl for pain management in children: a systematic review of the literature, J Pediatr Health Care, 25, 316, 10.1016/j.pedhc.2010.04.011 Borland, 2011, Equivalency of two concentrations of fentanyl administered by the intranasal route for acute analgesia in children in a paediatric emergency department: a randomized controlled trial, Emerg Med Australas, 23, 202, 10.1111/j.1742-6723.2011.01391.x 2010 Kharasch, 2004, Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate, Anesthesiology, 101, 729, 10.1097/00000542-200409000-00022 Takane, 2005, Rifampin reduces the analgesic effect of transdermal fentanyl, Ann Pharmacother, 39, 2139, 10.1345/aph.1G370 Sasson, 2006, Fentanyl patch sufficient analgesia for only one day, J Pain Symptom Manage, 31, 389, 10.1016/j.jpainsymman.2005.12.015 Morii, 2007, Failure of pain control using transdermal fentanyl during rifampicin treatment, J Pain Symptom Manage, 33, 5, 10.1016/j.jpainsymman.2006.08.005 Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) program. 2012. Available from http://www.tirfremsaccess.com. Fine, 2010, Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study, J Pain Symptom Manage, 40, 747, 10.1016/j.jpainsymman.2010.02.009 Markman, 2008, Not so fast: the reformulation of fentanyl and breakthrough chronic non-cancer pain, Pain, 136, 227, 10.1016/j.pain.2008.03.011 Passik, 2010, Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain, J Pain Symptom Manage, 41, 116, 10.1016/j.jpainsymman.2010.03.012 Nunez-Olarte, 2011, Emerging opioid abuse in terminal cancer patients taking oral transmucosal fentanyl citrate for breakthrough pain, J Pain Symptom Manage, 42, e6, 10.1016/j.jpainsymman.2011.07.006 Christie, 1998, Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain, J Clin Oncol, 16, 3238, 10.1200/JCO.1998.16.10.3238 Portenoy, 1999, Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled use titration study, Pain, 79, 303, 10.1016/S0304-3959(98)00179-1 Portenoy, 2006, A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer, Clin J Pain, 22, 805, 10.1097/01.ajp.0000210932.27945.4a Nalamachu, 2012, (2012) Successful dose finding with sublingual fentanyl tablet: combined results from 2 open-label titration studies, Pain Pract, 10.1111/j.1533-2500.2011.00525.x Nalamachu, 2011, Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain, Curr Med Res Opin, 27, 519, 10.1185/03007995.2010.545380 Davies, 2005, Oral transmucosal fentanyl citrate and xerostomia, J Pain Symptom Manage, 30, 496, 10.1016/j.jpainsymman.2005.11.006 Payne, 2001, Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain, J Pain Symptom Manage, 22, 575, 10.1016/S0885-3924(01)00306-2 Hanks, 2004, Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study, Palliat Med, 18, 698, 10.1191/0269216304pm966oa Darwish, 2008, Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects, Clin Drug Investig, 28, 1, 10.2165/00044011-200828010-00001 Weinstein, 2009, Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study, Cancer, 115, 2571, 10.1002/cncr.24279 Mercadante, 2011, Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose, J Pain Symptom Manage, 42, 464, 10.1016/j.jpainsymman.2010.12.010 Simpson, 2007, Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study, Clin Ther, 29, 588, 10.1016/j.clinthera.2007.04.007 Portenoy, 2007, Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study, Curr Med Res Opin, 23, 223, 10.1185/030079906X162818 Farrar, 2010, A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain, Pain Med, 11, 1313, 10.1111/j.1526-4637.2010.00939.x Shear, 2010, (2010) Transbuccal fentanyl for rapid relief of orthopedic pain in the ED, Am J Emerg Med, 28, 847, 10.1016/j.ajem.2009.04.011 Meda Pharmaceuticals Ltd. Personal communication, 2012. Insys Pharma. Personal communication, 2012.